Multiple Sclerosis Market Forecast

Multiple Sclerosis Market Forecast published by Datamonitor in July, 2010. This report price starts from US $ 15200.

Introduction

Introduction

With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono' s oral cladribine in the race to become the first oral multiple sclerosis therapy. Although growth will be stifled by biosimilars, these new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years (20092019).

Reasons to Purchase

• Quantify the current and future size of the multiple sclerosis drug class market and understand the main commercial opportunities and threats
• Assess key marketed and pipeline drugs, including new oral agents, Acorda' s Ampyra (dalfampridine) and GW Pharmaceuticals' Sativex (nabiximols).
• Understand the country-specific impact of key events in the multiple sclerosis market during the forecast period 2010 to 2019.

OVERVIEW

• This product contains forecasts for multiple sclerosis drugs across the seven major markets from 2010 to 2019. It has been designed for delivery in an excel data pack format.]
  • The associated report and PowerPoint presentation can be found under Latest research in the Knowledge centre, through the search function or by contacting your sales representative.
  • Introduction
  • Scope of this research
  • Research and analysis highlights
  • Key reasons to read this report
• Forecasting Methodology
  • The forecasting model:
  • General event information:
  • Event selection and quantification:
  • Event parameters:
• Disclaimer

Related Reports